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Abstract 31 
Naturally-occurring serine protease inhibitors of the Bowman-Birk family exert their potential 32 
chemopreventive and/or therapeutic properties via protease inhibition. In this study, we have 33 
quantified the amounts of active BBI isoinhibitors, IBB1 and IBBD2, in six commercial soymilks. 34 
By using cation exchange chromatography, the BBI isoinhibitors were isolated and their specific 35 
trypsin inhibitory activity was used to estimate their amounts in soymilk samples. IBB1 and IBBD2 36 
concentrations ranged from 0.44 to 5.20 and 0.27 to 4.60 mg/100 ml of soymilk, respectively; total 37 
BBI, considered as the sum of both isoinhibitors, ranged from 0.60 to 9.07 mg/100 ml of soymilk. 38 
These data show that physiologically relevant amounts of active BBI are present in commercial 39 
soymilk and may exert potential health-promoting effects.   40 
 41 
 42 
 43 
 44 
 45 
 46 
 47 
 48 
 49 
 50 
 51 
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1. Introduction 52 
In humans, aberrant functioning of certain serine proteases underlies pathological and physiological 53 
disorders.  The therapeutic value of protease inhibitors, both natural and synthetic, as modulators of 54 
such proteolytic activities in disease is well-recognized (Turk, 2006; Drag & Salvensen, 2010; Deu, 55 
Verdoes, & Bogyo, 2012). Within this framework, there is a growing interest in naturally-occurring 56 
serine protease inhibitors of the Bowman-Birk family due to their potential chemopreventive and/or 57 
therapeutic properties which can impact on several human diseases, including cancer, 58 
neurodegenerative disorders and inflammatory processes (Clemente, Marín-Manzano, Arques & 59 
Domoney, 2013). Bowman-Birk inhibitors (BBIs) from soybean (Glycine max) are the most 60 
extensively studied members of this protein family. Soybean BBI and homologous proteins have 61 
been demonstrated to be effective at preventing or suppressing radiation- and chemical carcinogen-62 
induced transformation, in a wide variety of in vitro assays and, carcinogenesis and inflammatory 63 
disorders in in vivo model systems (Kennedy, 1998; Clemente & Domoney, 2006; Carli et al., 2012; 64 
Magee, Owusu-Apenten, McCann, Gill & Rowland, 2012; Safavi & Rostami, 2012;). Experimental 65 
human trials utilizing BBI concentrate (BBIC), a protein extract of soybean enriched in BBI, have 66 
been completed in patients with oral leukoplakia, benign prostatic hyperplasia and ulcerative colitis. 67 
The strength of BBI doses in such intervention studies, measured in chymotrypsin inhibitory units 68 
(CIU), ranges from 25 to 800 CIU/d for a total of 6 months of BBIC treatment (Kennedy, 1998). 69 
The results of phase I clinical trials carried out with nineteen male patients with benign prostatic 70 
hyperplasia have shown that BBIC reduced prostate-specific antigen levels and prostate volume 71 
(Malkowicz et al., 2001). In the case of patients with ulcerative colitis, intake of BBIC was 72 
associated with a clinical response and induction of remission, as assessed by the Sutherland 73 
Disease Activity Index (an index that consists of four major criteria as follows: stool frequency, 74 
rectal bleeding, mucosal appearance, and physician rating of disease activity) (Lichtenstein, Deren, 75 
Katz, Lewis, & Kennedy, 2010); on the contrary, no clinical effects of BBIC in patients with oral 76 
leukoplakia were observed (Armstrong et al., 2013). Although the anti-nutritional effects of BBI 77 
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cannot be ignored, these intervention studies revealed that BBIC, orally administrated to human 78 
volunteers, was well-tolerated and no apparent toxicity or adverse side effects were elicited after 79 
long-term treatment.  80 
In soybean, two major classes of protease inhibitors, Kunitz (KTI) and BBI, accounts for about 81 
6% of the total seed protein (Brandon & Friedman, 2002). KTI is a 21 kDa protein with a single 82 
reactive site that binds trypsin. Soybean BBIs are proteins with molecular masses in the range of 6-83 
9 kDa and comprise two distinct binding loops, responsible for the inhibition of two enzyme 84 
molecules, which may be the same or distinct types of enzymes (Birk, 1985). Two BBI 85 
isoinhibitors, IBB1 and IBBD2, showing considerable amino acid sequence divergence within their 86 
inhibitory domains, are predominant in soybean cultivars; IBB1 inhibits both trypsin and 87 
chymotrypsin whereas IBBD2 inhibits trypsin only (Clemente, Moreno, Marín-Manzano, Jiménez, 88 
& Domoney, 2010).  89 
In order to quantify BBI in soy foods, enzymatic and immunological assays have been 90 
developed; however, no comprehensive information on the concentration of BBI in soy foods is 91 
currently available. The occurrence of BBI in soy foods (soymilk, soy infant formula, tofu, bean 92 
curd, soybean cake, and fermented soy products, among others) present in the US market is 93 
noteworthy, where BBI may be present in different amounts (Hernandez-Ledesma, Hsieh & de 94 
Lumen, 2009). The soy varieties used, the products themselves and the technological processes used 95 
in their preparations all contribute to variation in BBI concentration (Xiao, Wood, Robertson, & 96 
Gilani, 2012). In a recent study, BBI concentrations of twelve soymilk samples, ranging from 7.2 to 97 
55.9 mg BBI/100 mL of soymilk,  were reported (Hernandez-Ledesma et al., 2009). Such amounts 98 
seem to be physiologically relevant in order to exert anticancer effects in humans (Kennedy, 1998); 99 
nevertheless, these data are based on immunoreactive forms of BBI that could be functionally 100 
inactive. The emerging evidence suggests that soybean BBI exert their preventive and therapeutic 101 
properties via protease inhibition (Clemente, Sonnante, & Domoney, 2011). Thus, treatment of 102 
soybean BBI with reducing and alkylating agents, which substantially reduces inhibitory activity 103 
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against serine proteases, renders these dietary proteins unable to inhibit cell proliferation of colon 104 
cancer cells (Clemente et al., 2010). More recently, the anti-proliferative effect of rTI1B, a major 105 
pea BBI isoinhibitor expressed heterogously in Pichia pastoris, compared with those observed 106 
using a related inactive mutant, was evaluated (Clemente, Marín-Manzano, Arques, & Domoney, 107 
2012). The proliferation of HT29 colon cancer cells was significantly affected by rTI1B in a dose-108 
dependent manner, whereas the inactive mutant did not show any significant effect on colon cancer 109 
cell growth. These findings suggest that serine proteases should be considered as important targets 110 
in investigating the potential chemopreventive role of BBI during the early stages of colorectal 111 
carcinogenesis. 112 
Although active BBI seems to be necessary to exert their reported anti-carcinogenic and anti-113 
inflammatory properties, quantitative data regarding their presence in commercial soymilks has not 114 
been previously reported. Consequently, the aim of this study was to develop a suitable 115 
methodology that combines separation of protease isoinhibitors by liquid chromatography and 116 
further enzymatic determination of trypsin and chymotrypsin inhibitory activity in order to quantify 117 
the amounts of active BBI isoinhibitors, IBB1 and IBBD2, present in commercial soymilks that 118 
could exert potential health benefits to consumers. 119 
 120 
2. Materials and methods 121 
 122 
2.1 Materials 123 
 124 
BBI (T9777) and KTI (T2327) from soybean, trypsin (type III) and -chymotrypsin (type VII) 125 
from bovine pancreas, N- -benzoyl-DL-arginine-p-nitroanilide (BAPNA) and N-benzoyl-L-126 
tyrosine ethyl ester (BTEE) were obtained from Sigma (Alcobendas, Spain). All other chemicals 127 
were of analytical grade.  128 
 129 
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2.2 Isolation of soybean protease inhibitors  130 
A mixture of soybean BBI and KTI was prepared by dissolving 1 mg of each in 6 ml of 50 mM 131 
sodium acetate buffer, pH 4.4. The mixture was fractionated on a MonoS 5/50 GL cation exchange 132 
column (GE Healthcare, Uppsala, Sweden), connected to an AKTA FPLC system (GE Healthcare), 133 
using a linear gradient of 0-0.16 M NaCl in 50 mM sodium acetate buffer, pH 4.4, at a flow rate of 134 
1 mL/min. The elution was monitored at 280 nm and 0.5 mL fractions were collected. Trypsin 135 
inhibitory activity (TIA) measurements of eluted samples were carried out in flat-bottom microtitre 136 
plates by using BAPNA as specific substrate; the assay products were measured at 405 nm, as 137 
previously described (Clemente, Marin-Manzano, Jimenez & Rubio, 2008). Chymotrypsin 138 
inhibitory activity (CIA) evaluation of eluted samples was carried out by using BTEE as specific 139 
substrate, as described below (see section 2.5). 140 
 141 
2.3 Preparation of soymilk extracts 142 
 143 
Six commercial soymilks (SM-1 to SM-6) were purchased from local stores in Granada, Spain. 144 
Four samples (500 mL each) from the same lot/brand were individually freeze-dried and stored at -145 
20 °C.  Freeze-dried soymilk (500 mg) were added to 10 mL of 50 mM sodium acetate buffer, pH 146 
4.4, and stirred for 1 h at room temperature. The extracts were centrifuged at 3,500g for 15 min and 147 
the supernatants were dialysed extensively against 50 mM sodium acetate buffer, pH 4.4, at 4 °C. 148 
The soymilk preparations were fractionated on a MonoS 5/50 GL cation exchange column and 149 
monitored by TIA and CIA (see sections 2.2 and 2.5, respectively). The trypsin inhibitory profile of 150 
soymilks was used to define the chromatographic elution of their major protease inhibitors. 151 
 152 
2.4 Mass peptide fingerprinting 153 
 154 
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Isolated soybean protease inhibitors (10 µg) were dissolved in NuPAGE lithium dodecyl 155 
sulphate sample buffer (Invitrogen, Paisley, UK) and separated by electrophoresis on Novex 12% 156 
Bis–Tris pre-cast gels using 2-N-morpholine-ethane sulphonic acid (NuPAGE MES, Invitrogen) as 157 
running buffer. Immediately before use, samples were reduced with dithiothreitol (DTT) and 158 
NuPAGE antioxidant added to the upper buffer chamber to prevent re-oxidation of reduced proteins 159 
during electrophoresis. Bands were excised from Colloidal Blue (Invitrogen)-stained gels and 160 
subjected to in-gel trypsin digestion. Peptide fragments from digested proteins were desalted and 161 
concentrated using C-18 ZipTip columns (Millipore, Madrid, Spain) and then, loaded directly onto 162 
the matrix-assisted laser desorption/ionization (MALDI) plate, using a-cyano-4-hydroxycinnamic 163 
acid as the matrix for MALDI-mass spectrometry (MS) analysis. MS spectra were obtained 164 
automatically in a 4700 Proteomics Analyzer (Applied Biosystems, Cheshire, UK) operating in 165 
reflectron mode with delayed extraction. Peptide mass data were used for protein identification 166 
against the MS protein sequence database (www.matrixscience.com). 167 
 168 
2.5 Measurement of protease inhibitory activities  169 
 170 
The major BBI isoinhibitors, IBB1 and IBBD2, and Kunitz inhibitor were assessed for TIA 171 
and CIA. TIA was measured using a modified small-scale quantitative assay with BAPNA as 172 
specific substrate, and using 50 mM Tris, pH 7.5 as enzyme assay buffer. One trypsin inhibitor unit 173 
(TIU) was defined as that which gives a reduction in absorbance at 410 nm of 0.01, relative to 174 
trypsin control reactions, in 10 min in a defined assay volume of 10 mL (Domoney & Welham, 175 
1992). CIA was measured using BTEE as specific substrate. One chymotrypsin inhibitor unit (CIU) 176 
was defined as that which gives a reduction in absorbance at 256 nm of 0.01, relative to 177 
chymotrypsin control reactions, in 5 min in a defined assay volume of 10 mL, as previously 178 
described (Clemente, MacKenzie, Jeenes & Domoney, 2004). Specific TIA and CIA of IBB1, 179 
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IBBD2 and KTI, expressed as inhibitor units (IU) per mg of protein, were calculated. Such values 180 
were used to estimate the amount of individual protease inhibitors present in commercial soymilks.  181 
 182 
 183 
3. Results 184 
 185 
3.1 Isolation and functional characterization of major soybean BBI isoinhibitors, IBB1 and IBBD2, 186 
and Kunitz inhibitor 187 
As previously demonstrated by chromatographic, electrophoretic and mass peptide 188 
fingerprinting analyses, commercially available BBI consisted in a mixture of two major 189 
isoinhibitors, IBB1 and IBBD2, showing considerable amino acid sequence divergence within their 190 
inhibitory domains (Clemente et al., 2010). In the present study, a mixture of commercial BBI and 191 
KTI from soybean was fractionated by MonoS cation exchange chromatography. The elution 192 
pattern of the mixture of protease inhibitors, monitored by TIA and CIA measurements, is shown in 193 
Fig. 1a. Up to three major chromatographic peaks were resolved; at pH 4.4, peak 1 was not retained 194 
by the MonoS column whereas peaks 2 and 3 were bound and eluted in the range 0.05-0.08 M NaCl 195 
and 0.11-0.14 M NaCl, respectively. Regarding their protease inhibitory activities, peak 1 showed 196 
both TIA and CIA whereas peaks 2 and 3 demonstrated TIA only. The chromatographic fractions 197 
containing the three proteins were pooled individually and analysed by SDS-PAGE, and showed to 198 
correspond to the main electrophoretic bands present in the starting material (Fig. 1b). When 199 
alkylated, the purified peaks 1 and 2 showed proteins with apparent molecular masses in the range 200 
10-12 kDa whereas peak 3 showed a single electrophoretic band of 21 kDa. Further studies by mass 201 
peptide fingerprinting were carried out in order to reveal the identity of the three protease inhibitors. 202 
In-gel tryptic digestion of excised electrophoretic bands was performed followed by separation of 203 
the peptides generated and MS based analysis. A search of peptide mass data against the MS protein 204 
sequence database enabled the unambiguous identification of the protease inhibitors. The purified 205 
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proteins, corresponding to the chromatographic peaks 1, 2 and 3 (see Figure 1a), were identified as 206 
Bowman-Birk proteinase inhibitor (Swiss-Prot entry: IBB1_SOYBN), Bowman-Birk type 207 
proteinase inhibitor D-II (Swiss-Prot entry: IBBD2_SOYBN) and Kunitz inhibitor (Swiss-Prot 208 
entry: 1BA7_A), respectively, with sequence coverage ranging from 52 to 86 % (Table 1). An 209 
amino acid sequence comparison of IBBD2 and IBB1 proteins is shown in Table 2, where the 210 
peptide sequences that contributed to protein identification by MS are indicated. As described for 211 
other BBI proteins, IBB1 and IBBD2 contain 14 Cys residues in conserved positions (Clemente et 212 
al., 2011). Following the nomenclature of Schechter & Berger (1967), IBBD2 showed almost 213 
identical amino acid sequences within the inhibitory domains, except for positions P2´ and P4´; in 214 
both inhibitory domains, the P1 position is occupied by Arg, conferring specificity for inhibition of 215 
trypsin-like proteases. In the case of IBB1, variation at several positions within the two inhibitory 216 
domains was observed; the presence of Lys or Leu in position P1 confers specific inhibition of 217 
trypsin- or chymotrypsin-like proteases, respectively. In agreement with the identity of the P1 218 
residues of their inhibitory domains, IBB1 inhibited both trypsin and chymotrypsin, whereas 219 
IBBD2 inhibited trypsin only (Table 3). IBB1 showed a high specific CIA (2917 ± 292 CIU per mg 220 
of protein), in contrast to IBBD2, where CIA was not detected. IBBD2 showed a higher specific 221 
TIA than IBB1 (4919 ± 101 and 3828 ± 209 TIU per mg of protein, respectively). When compared 222 
with the BBI isoinhibitors, KTI showed lower specific TIA (2147 ± 105 TIU per mg of protein), 223 
being its ability to inhibit chymotrypsin almost null (Table 3). These significant differences in 224 
specific inhibitory activities are likely to reflect the variation in the amino acid sequences of the 225 
inhibitory domains that play an essential role in determining specificity and potency (Clemente & 226 
Domoney, 2006). 227 
 228 
3.2 Evaluation of protease inhibitors in soymilks 229 
 230 
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When monitored by TIA and CIA, the elution pattern of the six commercial soymilks was 231 
similar to that obtained for the mixture of protease inhibitors on cation exchange chromatography 232 
(Figure 2). The three chromatographic peaks obtained from the different soymilks were collected, 233 
being the protein identification of electrophoretic bands confirmed by mass peptide fingerprinting 234 
(not shown). The specific TIA was used to estimate the content of individual protease inhibitors 235 
(IBB1, IBBD2 and KTI) in commercial soymilks. IBB1 and IBBD2 concentrations ranged from 236 
0.44 to 5.20 and 0.27 to 4.60 mg/100 ml of soymilk, respectively; total BBI, considered as the sum 237 
of both isoinhibitors, ranged from 0.59 to 9.18 mg/100 ml of soymilk. In the case of KTI, its 238 
concentrations ranged from 1.82 to 5.50 mg/100 ml of soymilk (Table 4). 239 
 240 
4. Discussion 241 
 242 
BBIs appear to exert a protective effect against inflammatory disorders and cancer 243 
development; such beneficial effect has been specifically attributed to their intrinsic ability to 244 
inhibit serine proteases (Safavi & Rostami, 2012; Clemente et al., 2013). Inactive BBI forms render 245 
these dietary proteins unable to inhibit cell proliferation of colon cancer cells (Clemente et al., 246 
2010; 2012). These findings reveal the need to evaluate the amounts of active BBI present in soy 247 
foods that could potentially exert a beneficial effect to consumers. To quantify BBI in soy foods, 248 
enzymatic and immunological methods using polyclonal or monoclonal antibodies have been 249 
developed (Brandon, Bates & Friedman, 2004). By using western blotting analysis, Hernandez-250 
Ledesma et al. (2009) reported BBI concentrations ranging from 7.2 to 55.9 mg/100 ml of soymilk, 251 
showing most of the tested soymilks values higher than 23 mg/100 ml of soymilk. Although 252 
immunoassays offer the specificity and sensitivity necessary to recognize BBI in complex samples, 253 
they are unable to distinguish among active or inactive forms. In addition, unusual patterns of 254 
temperature-dependent binding displayed by monoclonal antibodies towards soybean BBI have 255 
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been reported (Brandon, Bates, & Friedman, 1989). Indeed, the lack of commercially available 256 
antibodies against BBI makes difficult to measure this protein quantitatively in soybean products 257 
that claim their reported health benefits (Losso, 2008). In the case of enzymatic inhibition, only 258 
functional BBI proteins with the ability to form complexes with digestive proteases, trypsin and 259 
chymotrypsin, can be evaluated (Clemente, Jiménez, Marín-Manzano & Rubio, 2008). Although 260 
enzymatic methods offer useful information about the overall protease inhibitory activity in 261 
complex samples, it gives no indication about which type of protease inhibitor is responsible of 262 
such activity (DiPietro & Liener, 1989). To distinguish the inhibitory activities among major 263 
soybean protease inhibitors, BBI and KTI, chromatographic fractionation of commercial soymilks 264 
prior to enzymatic inhibition measurements is strictly necessary. In view of that, we have isolated 265 
KTI and two major BBI isoinhibitors, IBB1 and IBBD2, from six commercial soymilks and 266 
quantified the corresponding amounts taken into account their specific TIA (Figure 2). The 267 
concentrations of active BBI, considered as the sum of IBB1 and IBBD2, ranged from 0.59 to 9.18 268 
mg/100 ml of soymilk whereas KTI ranged from 1.82 to 5.50 mg/100 ml of soymilk. The reported 269 
data reflects a significant variation on protease inhibitor concentrations among soymilks. The soy 270 
varieties used as well as the processing conditions might be responsible for the variability found in 271 
protease inhibitory activity among commercial soymilks. Given that beneficial effects of soybean 272 
BBI in humans seem to be dose-dependent, qualitative and quantitative differences on protease 273 
inhibitory activities among soymilks might be physiologically relevant.  274 
The amounts of protease inhibitors reported in this study points out their significant resistance 275 
to processing conditions during soymilk preparation. Heat treatment, a basic step of soymilk 276 
preparation, may reduce TIA content at some extent. In a recent study, Xiao et al. (2012) reported a 277 
TIA reduction of 44.4 % in soymilk when compared to that contained in whole soybean; 278 
unfortunately, no data regarding the survival rates of KTI and BBI were available. Whereas KTI is 279 
considered a heat-labile inhibitor, the ability of BBI to inhibit serine proteases seem not to be 280 
significantly diminished (Rouhana, Adler-Nissen, Cogan, & Frokiaer, 1996) except when prolonged 281 
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heat treatment at high temperature is applied (Rayas-Duarte, Bergeron, & Nielsen, 1992; Osman, 282 
Reid, & Weber, 2002). The rigid structure provided by the seven intra-molecular disulphide bridges 283 
that maintain the structural and functional features of the binding sites by adding covalent 284 
attachment to the inhibitor core are responsible of such high stability (Trivedi, Laurence, & 285 
Siahann, 2009; Bateman & James, 2011; Kumar & Gouda, 2013). It has been demonstrated that 286 
BBI from chickpea seeds can resist both acidic conditions and the action of digestive enzymes, and 287 
transit through the stomach and small intestine of pigs, generally held as a suitable model for human 288 
digestive physiology (Clemente et al., 2008). The presence of active BBI (at least 5-8 % of the total 289 
ingested BBI) at the terminal ileum revealed the resistance of a significant proportion of these 290 
proteins to the extreme conditions of the gastrointestinal tract in vivo. Chromatographic, 291 
electrophoretic and enzymatic data obtained from ileal samples suggested that most of the BBI 292 
activity is derived from a protein core containing the two binding domains, and resistant to 293 
proteolysis. In vitro incubation studies of soybean BBI with mixed fecal samples of pigs showed 294 
that BBI remained active and their intrinsic ability to inhibit serine proteases was not significantly 295 
affected by the enzymatic or metabolic activity of fecal microbiota (Marin-Manzano, Ruiz, 296 
Jimenez, Rubio, & Clemente, 2009). 297 
Purified BBI and BBIC has demonstrated to exert a protective and/or suppressive effect in 298 
dimethylhydrazine (DMH)-treated animals when used at concentrations as low as 10 mg/100 g diet, 299 
reducing the incidence and frequency of colon tumours in mice (St. Clair, Billings, Carew, Keller-300 
McGandy, Newberne, & Kennedy, 1990) and rats (Kennedy, Billings, Wan, & Newberne, 2002). 301 
Such amount would be equivalent to that present in a single serving of SM-2 and SM-4 and suggest 302 
that a single cup of soymilk could have some protective effect against cancer development if the 303 
results from animal studies are extrapolated to humans. Autoclaved BBIC, in which serine protease 304 
inhibitory activity was abolished, did not show any significant suppressive effect on colon tumour 305 
development in rodents, suggesting that the intrinsic ability of BBI to inhibit serine proteases may 306 
be required for their anti-cancer properties (Kennedy et al., 2002). Recent studies have 307 
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demonstrated a significant concentration- and time-dependent decrease in the growth of HT29 308 
human colon adenocarcinoma cells when treated with a mixture of IBB1 and IBBD2 (Clemente et 309 
al., 2010). These proteins have been shown to exert strong anti-proliferative effects of colon cancer 310 
cells at concentration as low as 20 µM and IC50 values in the range 40-50 µM; in contrast, the 311 
growth of non-malignant colonic fibroblastic CCD18-Co cells was unaffected. Interestingly, 312 
chemically inactivated soybean BBI did not demonstrate any significant effect of the proliferation 313 
of colon cancer cells suggesting that BBI exert their anti-proliferative properties via protease 314 
inhibition. In a recent study, a comparative study with rTI1B, a major pea BBI isoinhibitor 315 
expressed heterologously in Pichia pastoris, and a related synthetic mutant derivative lacking 316 
trypsin and chymotrypsin inhibitory activity was carried out (Clemente et al., 2002). Whereas the 317 
proliferation of HT29 colon cancer cells was inhibited significantly by rTI1B in a dose-dependent 318 
manner, the inactive mutant did not show any significant effect on colon cancer cell growth. These 319 
results support the relevance of quantify active BBI in soy-foods. 320 
The anti-carcinogenic properties of soybean BBI have been linked to the chymotrypsin 321 
inhibitory domain, leading to the hypothesis that chymotrypsin-like proteases are potential targets 322 
of BBI in anti-cancer effects (Kennedy et al., 2002). Yavelow, Collins, Birk, Troll, & Kennedy 323 
(1985) reported that an enzymatically modified soybean BBI having only chymotrypsin inhibitory 324 
activity was still fully effective as an inhibitor of radiation-induced transformation in vitro, whereas 325 
the BBI form which inhibits trypsin-like proteases only was ineffective. In contrast, it has been 326 
demonstrated recently that IBBD2, with ability to inhibit trypsin only, exerts anti-proliferative 327 
effects on colon cancer cells (Clemente et al., 2012). This is the first indication of the involvement 328 
of the trypsin inhibitory domain of BBI on health benefits and reveals that both trypsin- and 329 
chymotrypsin-like proteases involved in carcinogenic processes should be considered as potential 330 
targets of BBI. Due that both therapeutic targets and the action mechanism of soybean isoinhibitors, 331 
IBB1 and IBBD2 remain unknown, it is difficult to recognize the relevance of differences in terms 332 
of qualitative and quantitative inhibitory capacities among soymilks. Finally, recent studies suggest 333 
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that BBI may play an important role in the protection of other bioactive compounds present in 334 
soymilk against degradation or gut proteolysis. An example of such is lunasin, a 43-amino acid 335 
peptide with demonstrated chemopreventive action in both culture and animal models (Hernandez-336 
Ledesma et al., 2009; Hsieh, Hernandez-Ledesma, Jeong, Park, & de Lumen, 2010). 337 
In summary, this paper reports for first time the amounts of active protease inhibitors, 338 
distinguishing between KTI and two major BBI isoinhibitors, present in commercial soymilks. The 339 
results obtained in this study suggest that soymilk might be considered as a rich source of active 340 
BBI to exert potential health benefits. Research is needed to investigate the bioavailability of active 341 
BBI present in soymilks and to study their contribution in chronic disease prevention in healthy 342 
subjects. 343 
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Figure Captions 460 
 461 
Figure 1. A) Elution profile of a mixture of commercial Bowman-Birk isoinhibitors, IBB1 and 462 
IBBD2, and Kunitz inhibitor (KTI) from soybean on a MonoS 5/50 GL cation exchange column. 463 
Absorbance (mAU) at 280 nm of the chromatographic elution and the linear gradient of NaCl (0-464 
0.16 M) are shown (solid and dotted lines, respectively). Using BAPNA and BTEE as specific 465 
substrates, the trypsin (▲) and chymotrypsin (∆) inhibitory activities, measured on every fraction, 466 
are shown. B) SDS-PAGE under denaturing and reducing conditions of the mixture (lane b) and the 467 
chromatographic peaks 1 (lane c), 2 (lane d) and 3 (lane e) that contain purified protease inhibitors. 468 
Molecular weight markers are shown in lane a. 469 
 470 
Figure 2. Elution profile of six commercial soymilks on a MonoS 5/50 GL cation exchange 471 
column. Absorbance (mAU) at 280 nm of the chromatographic elution and the linear gradient of 472 
NaCl (0-0.16 M) are shown (solid and dotted lines, respectively). Using BAPNA and BTEE as 473 
specific substrates, the trypsin (▲) and chymotrypsin (∆) inhibitory activities, measured on every 474 
fraction, are shown. 475 
 476 
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Chromatographic  ID Protein name 
NCBI accession 
number 
Entry name 
Sequence 
coverage  
(%) 
Matched 
peptides 
Protein 
score
1 
       
1 
Bowman–Birk 
proteinase inhibitor 
GI:157830209 1BBI_A  52 3 123 
       
       
2 
Bowman-Birk 
proteinase inhibitor 
type D-II 
GI:350045 IBBDII  86 5 228 
       
       
3 
Trypsin Inhibitor A 
(Kunitz type) 
GI:3318877 1BA7_A 72 16 775 
Table 1. Identification of major Bowman-Birk isoinhibitors, IBB1 and IBBD2, and Kunitz inhibitor (KTI) separated by cation-exchange chromatography 
Database searching was performed using the MASCOT database (http://www.matrixscience.com). 
Protein scores greater than 57 were significant (P<0.05).  
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 504 
 505 
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 510 
   Table 2. Amino acid sequence alignment of IBB1 and IBBD2 
IBB1_SOYBN (GI:157830209)  - - - -- - - - - DDESSKPCCDQCACTKSNPPQCRCSDMRLNSCHSACKSCICALSYPAQCFCVDITDFCYEPCKPSEDDKEN 
IBBD2_SOYBN (GI:350045) SDQSSSYDDDEYSKPCCDLCMCTRSMPPQCSCEDIRLNSCHSDCKSCMCTRSQPGQCRCLDTNDFCYKPCKSRDD-------  
1----------------10----------------------20---------------------30---------------------40---------------------50---------------------60--------------------70------------------ 
Accession numbers are from MASCOT database (http://www.matrixscience.com). Amino acid sequences of inhibitory domains are underlined.  P
1
-P
1´ 
are the 
reactive peptide bond sites, in bold text. Either K or R at position P
1
 determines specificity for trypsin, whereas L determines specificity against chymotrypsin. The 
peptides that contributed to protein identification are indicated in italics. 
1-----------------10---------------------20----------------------30-------------------40----------------------50---------------------60---------------------70------------------ 
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 528 
Protease inhibitor 
  
Amino acid sequence 
of inhibitory domains 
  
Specific inhibitory activity 
(IU/mg protein) 
 Domain 1 Domain 2 TIA CIA 
IBB1 CTKSNPPQC CALSYPAQC 3,828 ± 209 2,917 ± 292 
IBBD2 CTRSMPPQC CTRSQPGQC 4,819 ± 101 ND 
KTI SPYRIR 
 
2,147 ± 105 78 ± 5 
Table 3.  Specific inhibitory activity for trypsin (T) and chymotrysin (C) of Bowman-Birk isoinhibitors, IBB1 and IBBD2, and Kunitz inhibitor (KTI) 
Specific activities values represent means ± SD from at least three independent determinations. P1-P1´are the reactive peptide bond 
sites, in bold text. Either K or R at position P1 determines specificity for trypsin, whereas L determines specificity against 
chymotrypsin. ND, not detected.  
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 Total TIA Total CIA IBB1 (mg) IBBD2 (mg) Total BBI1 (mg) KTI (mg) 
SM-1 6,853 ± 1,727 2,857 ± 382 0.44 ± 0.08 0.27 ± 0.05 0.71 ± 0.14 1.82 ± 0.58 
SM-2 50,857 ± 4,895 15,356 ± 1,308 4.63 ± 0.62 4.44 ± 0.71 9.07 ± 1.18 5.50 ± 0.39 
SM-3 11,858 ± 1,630 4,913 ± 305 1.11 ± 0.15 0.67 ± 0.15 1.77 ± 0.23 1.98 ± 0.20 
SM-4 43,295 ± 6,012 14,368 ± 2,888 5.20 ± 0.82 3.54 ± 0.46 8.74 ± 1.25 2.96 ± 0.17 
SM-5 8,495 ± 1,364 2,835 ± 171 0.49 ± 0.03 0.11 ± 0.03 0.60 ± 0.05 2.84 ± 0.48 
SM-6 12,839 ± 1,408 3,198 ± 251 0.80 ± 0.11 0.33 ± 0.04 1.12 ± 0.11 3.74 ± 0.44 
Table 4.  Protease inhibitory activity and quantitative determination of Bowman-Birk isoinhibitor, IBB1 and IBBD2, and Kunitz inhibitor (KTI) in 
six commercial soymilks 
Data are mean ± SD per 100 ml of soymilk from at least three independent determinations. Quantitative data of an individual protease inhibitor was calculated taking 
into account their corresponding specific inhibitory activities for trypsin (see Table 2).  
1
Total BBI is the sum of IBB1 and IBBD2. 
